Is Gilead Sciences About To Buy Vertex For $45 Billion?
April 29, 2015 at 22:33 PM EDT
Gilead Sciences has been rolling in the money since the release of its hepatitis C drug duo, Sovaldi and Harvoni. Now investors are wondering how Gilead will put its pile of cash to work.
